A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Gimsilumab
DRUG: Placebo

Sponsor

Kinevant Sciences GmbH

Collaborators

[object Object]